What is the recommended management of pregnancy in a patient with Polycythemia Vera, including safe medications, hematocrit control, and thrombosis prophylaxis?

Management of Polycythemia Vera in Pregnancy

All pregnant patients with PV should receive strict hematocrit control via phlebotomy (target <45%), low-dose aspirin (75-81 mg daily), and postpartum LMWH prophylaxis for 6 weeks, with pegylated interferon-α (45 mcg subcutaneously weekly) added for high-risk patients including those with prior thrombosis, recurrent fetal loss, prominent splenomegaly, or inadequate hematocrit control with phlebotomy alone 1.

Risk Stratification and Preconception Planning

Before conception, obtain a detailed obstetric history focusing on:

• Prior pregnancy losses (first trimester recurrent losses or late miscarriages)
• History of thrombosis (arterial or venous)
• Pregnancy complications (pre-eclampsia, IUGR, stillbirth, placental insufficiency/abruption)
• Extreme thrombocytosis (>1 million/μL) requiring acquired von Willebrand syndrome screening
• Cardiovascular risk factors requiring optimization 1

Critical point: Prior pregnancy loss is the most important predictor of subsequent fetal loss in myeloproliferative neoplasms, making obstetric history essential 1.

Medication Management

Discontinue Before Conception:

• Hydroxyurea - teratogenic, must be stopped in women contemplating pregnancy 1
• Warfarin - teratogenic 1
• Direct oral anticoagulants - not recommended during pregnancy 1

Safe Medications During Pregnancy:

Aspirin (75-81 mg daily):

• Continue throughout pregnancy in all PV patients 1, 2
• Hold 3 days prior to delivery if extreme thrombocytosis present to reduce neuraxial anesthesia bleeding risk 1

Phlebotomy:

• Maintain hematocrit strictly <45% (some protocols use <40% in first trimester) 1
• This is non-negotiable for all PV patients regardless of risk category 1, 2

Pegylated Interferon-α:

• Starting dose: 45 mcg subcutaneously weekly 1
• Mandatory indications: All high-risk patients with prior thrombosis history 1
• Consider in low-risk patients with: poorly controlled hematocrit, prominent splenomegaly, or recurrent fetal loss 1
• Associated with higher live birth rate (83%) 1
• Safe throughout pregnancy and can continue postpartum based on clinical parameters 1

Low Molecular Weight Heparin:

• Therapeutic dose: Required for patients with history of venous thrombosis, continued throughout pregnancy 1
• Interrupt 24 hours prior to cesarean delivery or neuraxial analgesia 1
• Prophylactic dose postpartum: All patients receive LMWH for 6 weeks postpartum due to highest VTE risk during this period 1, 2

Outcomes Without Aggressive Management

The evidence starkly demonstrates poor outcomes without protocol-driven care:

• In one UK series, only 1 live birth occurred in 7 pregnancies managed with standard antenatal care alone 2
• With aggressive intervention (hematocrit control, aspirin, LMWH), 10 of 11 pregnancies resulted in live births (p=0.0017) 2
• Live birth rates improve from approximately 14% to 91% with tailored management 2

Monitoring During Pregnancy

• Serial hematocrit monitoring with aggressive phlebotomy to maintain target
• Uterine artery Doppler examinations 2
• Regular fetal growth scanning 2
• If platelet count >1 million/μL: check ristocetin cofactor and multimer analysis to rule out acquired von Willebrand syndrome before continuing aspirin 1

Postpartum Management (Critical 6-Week Period)

Blood counts normalize within 4-6 weeks postpartum, but VTE risk is highest during this period 1:

• Continue aspirin 1
• Prophylactic LMWH for 6 weeks (not routinely given to all patients in some protocols, but recommended for those on antepartum therapy) 1
• Continue pegylated interferon-α in patients with thrombosis history 1
• Resume phlebotomy as needed for hematocrit control 1
• Vigilant count monitoring 1

Contraception Postpartum

• Avoid: Estrogen-based hormonal contraception 1
• Preferred: Non-hormonal or progesterone-based contraceptives 1

Common Pitfalls to Avoid

1. Underestimating thrombosis risk: Maternal thrombotic events occur in 6-8% of pregnancies even with treatment 1
2. Inadequate hematocrit control: This is the single most important modifiable risk factor 2
3. Stopping aspirin unnecessarily: Only hold if extreme thrombocytosis with acquired von Willebrand syndrome or 3 days before delivery 1
4. Inadequate postpartum prophylaxis: The 6-week postpartum period carries the highest VTE risk 1
5. Using hydroxyurea during pregnancy: Absolutely contraindicated despite being first-line outside pregnancy 1

The multidisciplinary approach with early involvement of high-risk obstetrics is essential, as pregnancy in PV carries significantly higher risk of fetal loss and complications compared to the general population 1.